Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 103

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 103
---
. While the use of topical antimicrobials is common practice for burn wounds, it is not clear if the topical antimicrobials prevent infection or simply select out more resistant organisms. More importantly, multiple studies have shown that systemic administration of antibiotics doesselect out resistant organisms. As such, it is recommended that prophylactic systemic antibiotics should be avoided in the treatment of burn patients (Greenhalgh 2024). The current standard of care for patients with severe burns requiring hospitalization still results in a significant annual number of burn-related deaths, the majority of which are due to invasive infection. This, in combination with the number of antibiotic-resistant strains on the rise, creates an urgent need for new, more effective therapies such as Gemini to prevent infection in severe burn patients 62 REVELATION’S PROGRAMS Gemini Platform Our current therapeutic candidates are all based on Gemini, our proprietary formulation of PHAD ®, a synthetic version of MPLA, that is known to stimulate the innate immune response via TLR4. The innate immune system is our first line of defense against stress such as trauma, infection and acute and chronic disorders. The innate immune system responds to stress (e.g. infection) by producing and releasing various types of cytokines. Cytokines are proteins that direct different activities in cells and can be inflammatory or protective, meaning they may be able to modulate certain established cellular activities. Toll-like receptors serve a vital role in initiating the innate immune system response by recognizing different molecular patterns associated with pathogens such as bacteria and viruses (e.g. PAMPS: pathogen associated molecular patterns) as well as tissue damage (e.g. DAMPS: damage associated molecular patterns). Revelation believes immunostimulatory preconditioning with Gemini prepares the body to respond better to stress due to infection, trauma, or other acute and chronic disorders. Modulated activities may include stimulation and recruitment of infection fighting immune cells, reduction of inflammation, and/or regulation of inflammation depending on the degree and nature of the stimulation which enables the multiple potential product indications in development. Figure 1: Interaction of PHAD with TLR4 Source: Revelation Biosciences 63 Gemini-AKI Program Overview Gemini is being evaluated as a potential therapy for the prevention of AKI due to external stress (e.g. surgical procedure, chemotherapy toxicity). We believe immunologic preconditioning with Gemini prepares the body to handle biologic stress by directing the body’s immune system to have an attenuated response to the stress. Gemini is being evaluated as a potential therapy for the prevention of AK